Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
May 13, 2020
QurAlis officially launches under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).
May 13, 2020
QurAlis raises a $42,000,000 series A round.
November 19, 2018
QurAlis raises a $5,500,000 seed round from BioInnovation Capital.
November 2018
QurAlis raises a $5,500,000 seed round from Amgen Ventures, BioInnovation Capital and MP Healthcare Venture Management.
Funding rounds
SBA Awards
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
QurAlis Raises $5.5 Million Seed Round
BusinessWire
Web
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Viva Biotech Holdings
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including...
Ben Adams
July 1, 2020
FierceBiotech
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
Ben Adams
May 13, 2020
FierceBiotech
QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
References
Is a
CompanyCompany attributes
Biotechnology
Biomedical engineering
Stem cellLocation
Cambridge, MassachusettsCrunchbase
MP Healthcare Venture Management
Amgen Ventures
BioInnovation Capital
Viva BiotechDUNS Number
080705732
Total funding amount (USD)
53,000,000
Latest funding round date
May 13, 2020
Latest funding type
Series A roundOther attributes
Country
United States
